# Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis

> **NCT05754710** · — · RECRUITING · sponsor: **Pfizer** · enrollment: 10 (estimated)

## Conditions studied

- Psoriatic Arthritis, Juvenile
- Polyarticular Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** Xeljanz

## Key facts

- **NCT ID:** NCT05754710
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-12
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05754710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05754710, "Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05754710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*